A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment
Phase of Trial: Phase IV
Latest Information Update: 24 May 2017
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms MOTION
- Sponsors Bayer
- 24 May 2017 Primary endpoint has been met (Living with Pulmonary Hypertension questionnaire (LPH)), according to results presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society.
- 19 May 2017 Data from this trial will be presented at the 2017 American Thoracic Society (ATS) International Conference, as reported in a Bayer media release.